HRTX Heron Therapeutics Inc

Price (delayed)

$0.3344

Market cap

$63.49M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.18

Enterprise value

$191.12M

?
Relative Growth: Rel. Growth: 18
Relative Strength: Rel. Strength: 1
Relative Valuation: Rel. Valuation: 35
Relative Profitability: Rel. Profitability: 19

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, ...

Highlights
The equity has surged by 125% year-on-year but it has declined by 24% since the previous quarter
The debt has declined by 16% year-on-year but it is up by 4.7% since the previous quarter
Heron Therapeutics's net income has decreased by 10% from the previous quarter
The gross margin has contracted by 6% YoY

Key stats

What are the main financial stats of HRTX

HRTX stock price

How has the Heron Therapeutics stock price performed over time
Intraday
-1.91%
1 week
-32.99%
1 month
-19.79%
1 year
-76.11%
YTD
-74.28%
QTD
-21.65%

Financial performance

How have Heron Therapeutics's revenue and profit performed over time
Revenue
$151.18M
Gross profit
$105.94M
Operating income
-$10.86M
Net income
-$34.05M
Gross margin
70.1%
Net margin
-22.5%
Heron Therapeutics's net income has decreased by 10% from the previous quarter
The net margin has declined by 10% since the previous quarter
The gross margin has contracted by 6% YoY
HRTX's gross profit is down by 5% year-on-year

Price vs fundamentals

How does HRTX's price correlate with its fundamentals

Growth

What is Heron Therapeutics's growth rate over time

Valuation

What is Heron Therapeutics stock price valuation
P/E
N/A
P/B
9.16
P/S
0.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.26
Heron Therapeutics's EPS has decreased by 6% QoQ
The equity has surged by 125% year-on-year but it has declined by 24% since the previous quarter
The P/B is 37% lower than the last 4 quarters average of 14.5
HRTX's price to sales (P/S) is 87% less than its 5-year quarterly average of 3.3 and 62% less than its last 4 quarters average of 1.1

Efficiency

How efficient is Heron Therapeutics business performance
Heron Therapeutics's ROE has soared by 73% from the previous quarter
Heron Therapeutics's return on sales has decreased by 14% QoQ
HRTX's ROA is down by 8% QoQ
The ROIC has grown by 3% from the previous quarter

Dividends

What is HRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HRTX.

Financial health

How did Heron Therapeutics financials performed over time
Heron Therapeutics's total assets is 2.8% higher than its total liabilities
Heron Therapeutics's total assets has increased by 9% YoY and by 2.5% QoQ
HRTX's total liabilities is down by 5% year-on-year but it is up by 3.5% since the previous quarter
The equity has surged by 125% year-on-year but it has declined by 24% since the previous quarter
The debt to equity is up by 39% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.